Global Opioid Induced Constipation (OIC) Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Opioid Induced Constipation (OIC) Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

According to our (Global Info Research) latest study, the global Opioid Induced Constipation (OIC) Drugs market size was valued at USD 2604.3 million in 2023 and is forecast to a readjusted size of USD 3520.9 million by 2030 with a CAGR of 4.4% during review period.

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.

North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.

In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

The Global Info Research report includes an overview of the development of the Opioid Induced Constipation (OIC) Drugs industry chain, the market status of Hospital Pharmacies (Lubiprostone, Methyl Naltrexone Bromide), Retail Pharmacies (Lubiprostone, Methyl Naltrexone Bromide), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Opioid Induced Constipation (OIC) Drugs.

Regionally, the report analyzes the Opioid Induced Constipation (OIC) Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Opioid Induced Constipation (OIC) Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Opioid Induced Constipation (OIC) Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Opioid Induced Constipation (OIC) Drugs industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Dose), revenue generated, and market share of different by Type (e.g., Lubiprostone, Methyl Naltrexone Bromide).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Opioid Induced Constipation (OIC) Drugs market.

Regional Analysis: The report involves examining the Opioid Induced Constipation (OIC) Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Opioid Induced Constipation (OIC) Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Opioid Induced Constipation (OIC) Drugs:

Company Analysis: Report covers individual Opioid Induced Constipation (OIC) Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Opioid Induced Constipation (OIC) Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital Pharmacies, Retail Pharmacies).

Technology Analysis: Report covers specific technologies relevant to Opioid Induced Constipation (OIC) Drugs. It assesses the current state, advancements, and potential future developments in Opioid Induced Constipation (OIC) Drugs areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Opioid Induced Constipation (OIC) Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Opioid Induced Constipation (OIC) Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Others

Market segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Major players covered
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Opioid Induced Constipation (OIC) Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Opioid Induced Constipation (OIC) Drugs, with price, sales, revenue and global market share of Opioid Induced Constipation (OIC) Drugs from 2019 to 2024.

Chapter 3, the Opioid Induced Constipation (OIC) Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Opioid Induced Constipation (OIC) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Opioid Induced Constipation (OIC) Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Opioid Induced Constipation (OIC) Drugs.

Chapter 14 and 15, to describe Opioid Induced Constipation (OIC) Drugs sales channel, distributors, customers, research findings and conclusion.